VIR / Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive more_horizontal

Vir Biotechnology Inc has faced a tough year so far, with shares declining by 54% year-to-date. Much of the company's underperformance is attributed t more_horizontal

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - EVP and Ch more_horizontal

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares more_horizontal

Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals. more_horizontal

Vir Biotechnology's shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type o more_horizontal

Vir Biotechnology has seen declining revenue because sales of its one marketed product, Sotrovimab, are declining. A phase 2 trial for an influenza A more_horizontal

Vir Biotechnology Inc. VIR, +0.92% said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals. The Phase 2 trial more_horizontal